EMA — authorised 11 November 2019
- Application: EMEA/H/C/004910
- Marketing authorisation holder: AstraZeneca AB
- Local brand name: Qtrilmet
- Indication: Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control. when already being treated with metformin and saxagliptin and dapagliflozin.
- Status: withdrawn